Sector and portfolio concentration
The group is concentrated in pharmaceuticals, medtech and assistive tech, so setbacks in one holding can matter.
- Scope
- Individual subsidiaries and end markets
- Materiality
- high
MedCap
MedCap is a Swedish investment and operating group that acquires and develops niche life science companies through majority-owned subsidiaries. Its portfolio is organized into three business areas: Assistive Tech, MedTech and Specialty Pharma, with companies run under their own brands but supported by group-level ownership and governance.
627
2.01
1.40
| % | |
|---|---|
| Assistive Tech | 35% Assistive technology businesses serving users and care environments with specialized products. |
| MedTech | 40% Medical technology products, software, components and packaging solutions for healthcare and life science customers. |
| Specialty Pharma | 25% Specialty pharmaceutical operations focused on niche products and related commercial activities. |
MedCap sells through its operating subsidiaries to healthcare and life science end markets rather than to a single end...
- Regions and public healthcare systemsprimary
Buy assistive technology and related solutions for care delivery and patient support.
- Hospitals and care providersprimary
Purchase medical technology products and software used in clinical workflows.
- Medtech manufacturerssecondary
Source components and packaging solutions that support device production and compliance.
- Nutrition and pharmaceutical companiessecondary
Buy packaging and related life science solutions for regulated products.
- Specialty pharma end marketssecondary
Use niche pharmaceutical products distributed through the group’s pharma operations.
MedCap is headquartered in Stockholm and operates as a Nordic life science owner with companies based mainly in...
- •Headquartered in Stockholm, Sweden
- •Core acquisition focus is companies based in northern Europe
- •Subsidiaries serve international markets beyond the Nordics
- •Operations are decentralized across independent portfolio companies
- •Cross-border sales and sourcing create currency and trade exposure
MedCap’s strategy is to acquire profitable niche life science companies and develop them through active ownership,...
01
Pursue acquisitions in niche life scienceshort-term
Acquisitions are a core growth engine and expand the portfolio.
02
Develop existing portfolio companiesmedium-term
Operational support and synergies are intended to improve each subsidiary's potential.
03
Use balance sheet capacity for growthmedium-term
Financial flexibility supports continued deal-making and portfolio expansion.
MedCap is exposed to sector concentration risk because its portfolio is focused on pharmaceuticals, medical technology...
Acquisition and integration risk
Growth depends on buying and developing companies, which can lead to valuation, integration and execution issues.
- Scope
- Add-on acquisitions and new core holdings
- Materiality
- high
Currency and trade exposure
Sales and purchases span multiple countries, creating FX and tariff sensitivity.
- Scope
- International operations and supply chains
- Materiality
- medium
Customer concentration in niche businesses
Smaller specialized companies can depend on a limited number of large customers or channels.
- Scope
- Hospitals, regions and industrial customers
- Materiality
- medium
Contingent consideration fair value
Can move reported earnings and net debt
Goodwill and intangible asset impairment
Potential write-downs if portfolio companies underperform
IFRS 16
IFRS 16 lease accounting
Changes reported net debt and EBITDA-based measures
Adjusted EBITA and items affecting comparability
Important for comparing acquisition-driven growth with recurring earnings
: 11/08/2026